Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Geisinger Health

Status and phase: Terminated; Phase 2

Conditions: Head and Neck Cancer

Treatments: Drug: Erlotinib

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00750555

OSI4178S

2008-0153

Details and patient eligibility

About

Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage III, IV SCCHN
• Completed curative treatment

Exclusion criteria

• Prior chemotherapy or radiotherapy
• Recurrent disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

1

Other group

Treatment:

Drug: Erlotinib